Company intelligence / Profile preview
Adolore BioTherapeutics
Delray Beach, Florida, United Statesadolore.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Adolore has demonstrated preclinical proof-of-concept for its CA8*-based gene therapies, showing long-lasting, locally acting analgesia in models of chronic osteoarthritis knee pain and erythromelalgia. The company is progressing toward IND filings and first-in-human clinical studies with support from NIH/NINDS grants. Manufacturing scale-up and additional preclinical animal studies are ongoing, with clinical batch production targeted for 2025 and human trials expected to begin in the first half of 2026
- Therapeutic areas
- CardiovascularRheumatology
- Modalities
- Gene therapyProtein therapeutics
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Advance Biological Laboratories / Institute Merieux subsidiary – manufacturing process development under NIH/NINDS HEAL program contract
Beyond the preview
Go deeper on Adolore BioTherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adolore BioTherapeutics.